Best of 2022 in prostate cancer and prostatic diseases
- PMID: 36739329
- DOI: 10.1038/s41391-023-00652-8
Best of 2022 in prostate cancer and prostatic diseases
References
-
- De Nunzio C, Amstrong AJ, Van Oort I, Dorff T. Editor’ summary: A paradigm shift in castration-resistant prostate cancer management. Prostate Cancer Prostatic Dis. 2022;25:601–3. https://doi.org/10.1038/S41391-022-00574-X - DOI - PubMed
-
- Frisbie JW, Van Besien AJ, Lee A, Xu L, Wang S, Choksi A, et al. PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer Prostatic Dis. 2022; https://doi.org/10.1038/s41391-022-00549-y
-
- Beetz NL, Dräger F, Hamm CA, Shnayien S, Rudolph MM, Froböse K, et al. MRI-targeted biopsy cores from prostate index lesions: assessment and prediction of the number needed. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00599-2
-
- Noujeim JP, Belahsen Y, Lefebvre Y, Lemort M, Deforche M, Sirtaine N, et al. Optimizing multiparametric magnetic resonance imaging-targeted biopsy and detection of clinically significant prostate cancer: the role of perilesional sampling. Prostate Cancer Prostatic Dis. 2022; https://doi.org/10.1038/s41391-022-00620-8
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical